Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E34.29 EPS (ttm)2.21 Insider Own0.06% Shs Outstand2.66B Perf Week1.50%
Market Cap201.25B Forward P/E16.06 EPS next Y4.71 Insider Trans-48.29% Shs Float2.60B Perf Month0.49%
Income5.95B PEG3.60 EPS next Q1.05 Inst Own77.90% Short Float1.82% Perf Quarter6.15%
Sales41.73B P/S4.82 EPS this Y29.20% Inst Trans-0.02% Short Ratio3.33 Perf Half Y20.11%
Book/sh12.18 P/B6.21 EPS next Y8.43% ROA3.90% Target Price81.32 Perf Year21.88%
Cash/sh3.86 P/C19.57 EPS next 5Y9.52% ROE10.10% 52W Range52.83 - 80.19 Perf YTD-1.06%
Dividend2.20 P/FCF53.44 EPS past 5Y-1.90% ROI8.70% 52W High-5.72% Beta0.72
Dividend %2.91% Quick Ratio1.20 Sales past 5Y-3.20% Gross Margin67.40% 52W Low43.10% ATR1.73
Employees69000 Current Ratio1.40 Sales Q/Q4.50% Oper. Margin17.80% RSI (14)52.50 Volatility1.81% 2.33%
OptionableYes Debt/Eq0.73 EPS Q/Q- Profit Margin8.00% Rel Volume1.15 Prev Close75.60
ShortableYes LT Debt/Eq0.61 EarningsFeb 01 BMO Payout152.00% Avg Volume14.17M Price75.60
Recom1.70 SMA201.30% SMA500.11% SMA20012.47% Volume0 Change0.00%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-17-19 07:06PM  Pacira's Study on Exparel Label Expansion Meets Endpoints Zacks
06:57PM  Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA Zacks
02:40PM  Nasdaq Leads Dow Jones In Bullish Upturn; These 4 Blue Chips Are Outpacing Apple, Forming Chart Patterns Investor's Business Daily
01:54PM  Bull Signal Flashing for This Healthcare Stock Schaeffer's Investment Research
12:47PM  Here's Yana Barton's 2019 stock picks CNBC Videos
08:12AM  3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group InvestorPlace
Jan-15-19 03:04PM  3 of the Top Big Pharma Stocks to Buy Now InvestorPlace
09:27AM  Stock Market News For Jan 15, 2019 Zacks
07:07AM  3 Big Stock Charts for Tuesday: Broadcom, Facebook and Merck InvestorPlace
Jan-14-19 06:05PM  5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019 Zacks
05:24PM  Stocks slip as corporate earnings season begins Yahoo Finance Video
05:00PM  Mercks KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS 10) Business Wire
08:39AM  What's in Store for Merck in 2019 After a Solid Run in '18? Zacks
Jan-13-19 06:31PM  Here's Why Merck & Co. Surged 35.8% in 2018 Motley Fool
Jan-11-19 06:11PM  NASH Space in Focus in 2019 as Firms Look to Diversify Zacks
05:36PM  5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019 Zacks
09:45AM  Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet Zacks
09:38AM  Dow 30 Stock Roundup: Boeing Q4 Commercial Deliveries Up Y/Y, Merck Buys NASH Candidate Zacks
09:04AM  3 Biotech Stocks Bubbling Away Investopedia
06:22AM  4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 Zacks
Jan-10-19 09:56AM  Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting Zacks
Jan-09-19 12:13PM  Moderna Soars After Update of Its Pipeline Programs GuruFocus.com
10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
08:31AM  Novartis' Crizanlizumab Gets Breakthrough Therapy Status Zacks
08:24AM  Dow Posts Longest Winning Run Since November: 5 Top Picks Zacks
Jan-08-19 02:11PM  Is It Time to Sell Celgene Stock After the Bristol-Myers Squibb Offer? InvestorPlace
11:07AM  Moderna Shares Jump on Positive Cancer-Treatment Progress TheStreet.com
08:48AM  Moderna's stock jumps after progress report on cancer treatments MarketWatch
08:00AM  Dogs of the Dow Win in 2018: Will ETFs See Success in 2019? Zacks
Jan-07-19 06:16PM  Top Dow Stocks for 2018 Investopedia
05:45PM  Merck (MRK) Stock Sinks As Market Gains: What You Should Know Zacks
05:35PM  Spiros Segalas' 5 Biggest Stock Buys of 4th Quarter GuruFocus.com
01:31PM  U.S. Supreme Court could side with Merck over Fosamax lawsuits Reuters
11:50AM  U.S. Supreme Court could side with Merck over Fosamax lawsuits Reuters
10:29AM  Merck loses bid to revive $200 million Gilead verdict at U.S. high court Reuters
09:54AM  Merck loses bid to revive $200 mln Gilead verdict at U.S. high court Reuters
09:27AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
09:22AM  Justice Ruth Bader Ginsburg missing oral arguments for first time in 25 years on Supreme Court CNBC
09:09AM  Gilead (GILD) Collaborates With Yuhan for NASH Candidates Zacks
04:00AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie Zacks
Jan-04-19 04:24PM  Bristol To Become Top 5 Pharma And Other Fallout From Celgene Takeover Investor's Business Daily
10:13AM  Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout InvestorPlace
10:07AM  Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate Zacks
09:36AM  Bristol-Myers to Acquire Leading Biotech Celgene for $74B Zacks
07:29AM  Pfizer Begins Pivotal Study on Alopecia Areata Candidate Zacks
06:50AM  Today's Research Reports on Trending Tickers: Johnson & Johnson and Merck & Co. ACCESSWIRE
06:17AM  Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan Zacks
Jan-03-19 05:51PM  The Top Healthcare Stocks of 2018: Can They Continue in 2019? Motley Fool
03:49PM  Bristol-Myers' (BMY) Sprycel Gets FDA Nod for Label Expansion Zacks
03:27PM  P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade Moody's
08:48AM  UPDATE: Cocrystal Pharma to work with Merck on flu therapy, sending shares up 32% premarket MarketWatch
06:53AM  Merck's Keytruda wins 5 new approvals in Japan MarketWatch
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors Business Wire
06:30AM  Merck Exercises Option for NGM Bios Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes Business Wire
Jan-02-19 04:28PM  Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy Zacks
04:27PM  Could This New Biotech IPO Could Score Big With A Cancer Vaccine? Investor's Business Daily
06:45AM  Merck to Participate at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
06:30AM  BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase 2019 and Presentation at Keystone Symposia Conference GlobeNewswire
Dec-31-18 04:56PM  What Happened in the Stock Market Today Motley Fool
04:25PM  This Is The Top Dow Stock Of 2018 And It's Not Even Close Investor's Business Daily
04:05PM  Stocks Today Brush Off The Bears; Will These 4 Lead The Dow Jones In 2019? Investor's Business Daily
11:41AM  The best and worst stocks of 2018 MarketWatch
08:13AM  Dow Jones Futures Jump, But Here's A Stock Market Rally Reality Check Investor's Business Daily
08:12AM  The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon Zacks
Dec-30-18 03:27PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-28-18 05:45PM  Merck (MRK) Stock Moves -0.01%: What You Should Know Zacks
04:55PM  BioXcel Surges on Fast Track Designation to Agitation Drug Zacks
01:49PM  Top Analyst Reports for Merck, Abbott & Lockheed Martin Zacks
07:25AM  Analysis: Positioning to Benefit within General Motors, RE/MAX, Genworth Financial, Merck & Co., Aerojet Rocketdyne, and Fluor Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-27-18 09:51AM  Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine Zacks
08:37AM  Buy 5 Dow Stocks to Strengthen Your Portfolio in 2019 Zacks
08:20AM  Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019 Zacks
Dec-26-18 02:32PM  Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine GlobeNewswire
02:14PM  Eversept Partners Return, AUM, and Holdings Insider Monkey
01:25PM  Will Big Pharma's Giant Maw Scoop Up These Small-Cap Players? Investor's Business Daily
01:04PM  Bristol-Myers Squibb Stock Is Coming Back Slow, but Thats Fine InvestorPlace
Dec-24-18 12:35PM  Dow Jones Falls 3,700 Points For The Month; This Blue-Chip Stock Triggers Sell Signal Investor's Business Daily
09:08AM  Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study Zacks
Dec-22-18 12:00PM  Better Buy: AbbVie vs. Merck Motley Fool
Dec-21-18 02:55PM  Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study Reuters
02:12PM  Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study Reuters
02:00PM  Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer PR Newswire
09:31AM  Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study Zacks
09:13AM  Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations Zacks
08:57AM  Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review Zacks
08:53AM  Dow 30 Stock Roundup: Nike, Walgreens Boots Earnings Impress Zacks
08:14AM  5 S&P 500 Stocks Stand Tall Despite Index's Loss of 2018 Gains Zacks
06:04AM  Do Directors Own Merck & Co., Inc. (NYSE:MRK) Shares? Simply Wall St.
Dec-20-18 06:11PM  Bristol-Myers to Sell French Consumer Health Unit for $1.6B Zacks
05:34PM  AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting Zacks
04:15PM  Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial Business Wire
10:15AM  Merck's Keytruda Gets FDA Approval for Rare Skin Cancer Zacks
10:01AM  3 Stocks Billionaire Dan Loeb Bought in Q3 (and 2 He Dumped) Insider Monkey
08:48AM  5 Blue Chip Stocks to Lead Despite Rising Global Shocks Investopedia
06:30AM  LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer Business Wire
03:02AM  AstraZeneca's ovarian cancer and anaemia treatments meet goals in late-stage studies Reuters
02:57AM  AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies Reuters
Dec-19-18 04:38PM  AstraZeneca's ovarian cancer drug gets FDA nod as maintenance treatment Reuters
04:13PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer Business Wire
03:16PM  LYNPARZA® (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., Daiichi Sankyo Company, Limited, Cold Genesys, Inc., Kyn Therapeutics, and Instituto Butantan. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM